Published in Oncogene on October 29, 1998
Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology (2008) 5.19
Molecular aspects of thyroid hormone actions. Endocr Rev (2010) 3.29
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Nonperiodic activity of the human anaphase-promoting complex-Cdh1 ubiquitin ligase results in continuous DNA synthesis uncoupled from mitosis. Mol Cell Biol (2000) 1.74
Aberrant accumulation of PTTG1 induced by a mutated thyroid hormone beta receptor inhibits mitotic progression. J Clin Invest (2006) 1.37
Ectopic expression of PTTG1/securin promotes tumorigenesis in human embryonic kidney cells. Mol Cancer (2005) 1.34
Downregulation of the anaphase-promoting complex (APC)7 in invasive ductal carcinomas of the breast and its clinicopathologic relationships. Breast Cancer Res (2005) 1.20
Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res (2001) 1.19
PTTG1 oncogene promotes tumor malignancy via epithelial to mesenchymal transition and expansion of cancer stem cell population. J Biol Chem (2012) 1.13
PTTG/securin activates expression of p53 and modulates its function. Mol Cancer (2004) 1.11
Regulation of angiogenesis and invasion by human Pituitary tumor transforming gene (PTTG) through increased expression and secretion of matrix metalloproteinase-2 (MMP-2). Mol Cancer (2006) 1.07
Pituitary tumor transforming gene interacts with Sp1 to modulate G1/S cell phase transition. Oncogene (2007) 1.06
PTTG: an important target gene for ovarian cancer therapy. J Ovarian Res (2008) 1.01
Overexpressed hPTTG1 promotes breast cancer cell invasion and metastasis by regulating GEF-H1/RhoA signalling. Oncogene (2011) 1.01
Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol (2006) 0.99
Induction of Dlk1 by PTTG1 inhibits adipocyte differentiation and correlates with malignant transformation. Mol Biol Cell (2009) 0.98
Multiple myeloma phosphotyrosine proteomic profile associated with FGFR3 expression, ligand activation, and drug inhibition. Proc Natl Acad Sci U S A (2009) 0.96
Expression of pituitary tumor transforming gene in human gastric carcinoma. World J Gastroenterol (2004) 0.94
The emerging role of pituitary tumor transforming gene in tumorigenesis. Clin Med Res (2006) 0.92
Inhibition of pituitary tumor-transforming gene-1 in thyroid cancer cells by drugs that decrease specificity proteins. Mol Carcinog (2011) 0.92
Overexpression of the pituitary tumor transforming gene induces p53-dependent senescence through activating DNA damage response pathway in normal human fibroblasts. J Biol Chem (2010) 0.91
Securin (hPTTG1) expression is regulated by beta-catenin/TCF in human colorectal carcinoma. Br J Cancer (2006) 0.90
Securin is a target of the UV response pathway in mammalian cells. Mol Cell Biol (2004) 0.89
Gene expression profiling of breast cancers with emphasis of beta-catenin regulation. J Korean Med Sci (2004) 0.87
Novel functions of thyroid hormone receptor mutants: beyond nucleus-initiated transcription. Steroids (2006) 0.86
Glycogen synthase kinase-3beta (GSK3beta) negatively regulates PTTG1/human securin protein stability, and GSK3beta inactivation correlates with securin accumulation in breast tumors. J Biol Chem (2011) 0.84
Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br J Cancer (2008) 0.84
PTTG2 silencing results in induction of epithelial-to-mesenchymal transition and apoptosis. Cell Death Dis (2013) 0.83
The influence of the pituitary tumor transforming gene-1 (PTTG-1) on survival of patients with small cell lung cancer and non-small cell lung cancer. J Carcinog (2006) 0.82
RNAi-mediated knockdown of pituitary tumor- transforming gene-1 (PTTG1) suppresses the proliferation and invasive potential of PC3 human prostate cancer cells. Braz J Med Biol Res (2012) 0.82
Effect of PTTG on endogenous gene expression in HEK 293 cells. BMC Genomics (2009) 0.81
Construction and clarification of dynamic gene regulatory network of cancer cell cycle via microarray data. Cancer Inform (2007) 0.81
The pituitary tumor transforming gene 1 (PTTG-1): an immunological target for multiple myeloma. J Transl Med (2008) 0.81
Isolation and characterization of novel pituitary tumor related genes: a cDNA representational difference approach. Mol Cell Endocrinol (2010) 0.81
Pituitary tumor-transforming gene expression is a prognostic marker for tumor recurrence in squamous cell carcinoma of the head and neck. BMC Cancer (2006) 0.81
Downregulation of protein tyrosine phosphatase PTPL1 alters cell cycle and upregulates invasion-related genes in prostate cancer cells. Clin Exp Metastasis (2012) 0.80
PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma. J Hematol Oncol (2015) 0.79
Roles of miR-186 and PTTG1 in colorectal neuroendocrine tumors. Int J Clin Exp Med (2015) 0.78
Methylation alterations are not a major cause of PTTG1 misregulation. BMC Cancer (2008) 0.77
Securin promotes the identification of favourable outcome in invasive breast cancer. Br J Cancer (2009) 0.76
Down-regulation of the oncogene PTTG1 via the KLF6 tumor suppressor during induction of myeloid differentiation. PLoS One (2013) 0.76
Cloning of Porcine Pituitary Tumor Transforming Gene 1 and Its Expression in Porcine Oocytes and Embryos. PLoS One (2016) 0.75
Bridging Ral GTPase to Rho pathways. RLIP76, a Ral effector with CDC42/Rac GTPase-activating protein activity. J Biol Chem (1995) 2.69
Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine? Leuk Res (2011) 2.23
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia (2011) 2.12
STAT-related transcription factors are constitutively activated in peripheral blood cells from acute leukemia patients. Blood (1996) 1.99
A tomato cDNA inducible by salt stress and abscisic acid: nucleotide sequence and expression pattern. Plant Mol Biol (1990) 1.90
GMAP-210, A cis-Golgi network-associated protein, is a minus end microtubule-binding protein. J Cell Biol (1999) 1.80
Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia (2010) 1.75
Brief report: treatment of adult T-cell leukemia-lymphoma with zidovudine and interferon alfa. N Engl J Med (1995) 1.67
Response to antiviral treatment in hepatitis C virus-associated marginal zone lymphomas. Leukemia (2004) 1.62
cis-element combinations determine phenylalanine ammonia-lyase gene tissue-specific expression patterns. Plant Cell (1992) 1.60
Y chromosome markers and Trans-Bering Strait dispersals. Am J Phys Anthropol (1997) 1.60
Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. J Immunol (1991) 1.60
PI-103, a dual inhibitor of Class IA phosphatidylinositide 3-kinase and mTOR, has antileukemic activity in AML. Leukemia (2008) 1.55
A probable lipid transfer protein gene is induced by NaCl in stems of tomato plants. Plant Mol Biol (1992) 1.53
Genes from mycoparasitic fungi as a source for improving plant resistance to fungal pathogens. Proc Natl Acad Sci U S A (1998) 1.50
Timing of spontaneous recanalization and risk of hemorrhagic transformation in acute cardioembolic stroke. Stroke (2001) 1.49
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial. J Clin Oncol (1995) 1.48
Cloning and characterization of a chitinase (chit42) cDNA from the mycoparasitic fungus Trichoderma harzianum. Curr Genet (1994) 1.47
Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS (1992) 1.47
Differential accumulation of S-adenosylmethionine synthetase transcripts in response to salt stress. Plant Mol Biol (1994) 1.46
Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM). Bone Marrow Transplant (2000) 1.44
Mutation in RAP1 is a rare event in myelodysplastic syndromes. Leukemia (2005) 1.44
An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol (1989) 1.43
Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg (2008) 1.43
Activity of the caspase-3/CPP32 enzyme is increased in "early stage" myelodysplastic syndromes with excessive apoptosis, but caspase inhibition does not enhance colony formation in vitro. Exp Hematol (2000) 1.43
Expression, tissue distribution and subcellular localization of dehydrin TAS14 in salt-stressed tomato plants. Plant Mol Biol (1994) 1.40
Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients-report of the French society of bone marrow transplantation. J Clin Oncol (2000) 1.39
SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38
Isolation and characterization of three chitinases from Trichoderma harzianum. Eur J Biochem (1992) 1.38
The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Leukemia (2011) 1.37
hpttg is over-expressed in pituitary adenomas and other primary epithelial neoplasias. Oncogene (1999) 1.34
Increased Antifungal Activity of Trichoderma harzianum Transformants That Overexpress a 33-kDa Chitinase. Phytopathology (1999) 1.23
Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias. Lancet (1987) 1.22
Grb2 and its apoptotic isoform Grb3-3 associate with heterogeneous nuclear ribonucleoprotein C, and these interactions are modulated by poly(U) RNA. J Biol Chem (1998) 1.22
A novel endo-beta-1,3-glucanase, BGN13.1, involved in the mycoparasitism of Trichoderma harzianum. J Bacteriol (1995) 1.21
A conditionally expressed third partner stabilizes or prevents the formation of a transcriptional activator in a three-hybrid system. J Biol Chem (1997) 1.20
Human securin, hPTTG, is associated with Ku heterodimer, the regulatory subunit of the DNA-dependent protein kinase. Nucleic Acids Res (2001) 1.19
Purification and characterization of an endo-beta-1,6-glucanase from Trichoderma harzianum that is related to its mycoparasitism. J Bacteriol (1995) 1.19
Failure of teicoplanin therapy in two neutropenic patients with staphylococcal septicemia who recovered after administration of vancomycin. Eur J Clin Microbiol Infect Dis (1990) 1.18
Cell cycle regulated expression and phosphorylation of hpttg proto-oncogene product. Oncogene (2000) 1.14
Primary structure and expression pattern of the 33-kDa chitinase gene from the mycoparasitic fungus Trichoderma harzianum. Curr Genet (1995) 1.09
A new member of the amphiphysin family connecting endocytosis and signal transduction pathways. J Biol Chem (1997) 1.08
[Mixed cryoglobulinemia, membranoproliferative glomerulonephritis, and chronic hepatitis C. Sequential treatment with immunosuppressors and interferon]. Med Clin (Barc) (1994) 1.07
A high-affinity binding protein for the regulatory subunit of cAMP-dependent protein kinase II in the centrosome of human cells. Exp Cell Res (1993) 1.07
High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol (2006) 1.07
Ultraearly hematoma growth predicts poor outcome after acute intracerebral hemorrhage. Neurology (2011) 1.06
Molecular characterization and heterologous expression of an endo-beta-1,6-glucanase gene from the mycoparasitic fungus Trichoderma harzianum. Mol Gen Genet (1995) 1.04
Evi-1 expression in leukemic patients with rearrangements of the 3q25-q28 chromosomal region. Leukemia (1992) 1.03
hSiah2 is a new Vav binding protein which inhibits Vav-mediated signaling pathways. Mol Cell Biol (1999) 1.02
Proliferative potential after DNA damage and non-homologous end joining are affected by loss of securin. Cell Death Differ (2007) 1.01
Time course of tissue plasminogen activator-induced recanalization in acute cardioembolic stroke: a case-control study. Stroke (2001) 1.01
Regulation of chitinase 33 (chit33) gene expression in Trichoderma harzianum. Curr Genet (2001) 1.01
A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse. Leukemia (2013) 1.01
Acute-phase response, interleukin-6, and alteration of cyclosporine pharmacokinetics. Clin Pharmacol Ther (1994) 1.01
Is intensive care justified for patients with haematological malignancies? Intensive Care Med (1990) 0.99
Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients. Leukemia (2005) 0.97
Detection of a physical and functional interaction between Csk and Lck which involves the SH2 domain of Csk and is mediated by autophosphorylation of Lck on tyrosine 394. J Biol Chem (1996) 0.97
High-dose chemoradiotherapy and autologous blood stem cell transplantation in multiple myeloma: results of a phase II trial involving 63 patients. Blood (1993) 0.96
Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes. Leukemia (1997) 0.96
[Cardiac localization of non Hodgkin's lymphoma: a study on four cases]. Rev Med Interne (2003) 0.96
Blood-brain barrier disruption highly induces aquaporin-4 mRNA and protein in perivascular and parenchymal astrocytes: protective effect by estradiol treatment in ovariectomized animals. J Neurosci Res (2005) 0.96
Isolation of ntrA-like mutants of Azotobacter vinelandii. J Bacteriol (1986) 0.95
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide. Leuk Res (2008) 0.95
nasST, two genes involved in the induction of the assimilatory nitrite-nitrate reductase operon (nasAB) of Azotobacter vinelandii. Mol Microbiol (1995) 0.94
In vitro binding and phosphorylation of human immunodeficiency virus type 1 Nef protein by serine/threonine protein kinase. J Gen Virol (1995) 0.94
Efficacy and tolerability of prolonged linezolid therapy in the treatment of orthopedic implant infections. Eur J Clin Microbiol Infect Dis (2007) 0.94
Structural interpretation of site-directed mutagenesis and specificity of the catalytic subunit of protein kinase CK2 using comparative modelling. Protein Eng (1999) 0.93
Identification of an operon involved in the assimilatory nitrate-reducing system of Azotobacter vinelandii. Mol Microbiol (1993) 0.93
Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes. J Biol Chem (1994) 0.93
The proline-rich region of Vav binds to Grb2 and Grb3-3. Oncogene (1995) 0.92
Self-administered joint counts in rheumatoid arthritis: comparison with standard joint counts. J Rheumatol (1999) 0.91
Spontaneous dissection of intracranial vertebral artery: clinical recovery with conservative treatment. J Neurol Neurosurg Psychiatry (1986) 0.91
[Neurological manifestations of fat embolism syndrome]. Neurologia (1995) 0.91
Breed effect on carcass and meat quality of foals slaughtered at 24months of age. Meat Sci (2009) 0.91
A putative catabolite-repressed cell wall protein from the mycoparasitic fungus Trichoderma harzianum. Mol Gen Genet (1994) 0.91
Multiple sclerosis prevalence in Malaga, Southern Spain estimated by the capture-recapture method. Mult Scler (2011) 0.91
Flow cytometric detection of dyserythropoiesis: a sensitive and powerful diagnostic tool for myelodysplastic syndromes. Leukemia (2013) 0.91
Study of tuberculous meningitis by CT. Neuroradiology (1980) 0.91
Melatonin attenuates acute renal failure and oxidative stress induced by mercuric chloride in rats. Am J Physiol Renal Physiol (2000) 0.90
Intensified-dose (4 gm/m2) cyclophosphamide and granulocyte colony-stimulating factor administration for hematopoietic stem cell mobilization in refractory rheumatoid arthritis. Arthritis Rheum (1999) 0.90
A G polymorphism in the CRBN gene acts as a biomarker of response to treatment with lenalidomide in low/int-1 risk MDS without del(5q). Leukemia (2013) 0.90
A role for JNK/SAPK in proliferation, but not apoptosis, of IL-3-dependent cells. Curr Biol (1997) 0.90
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leuk Res (2011) 0.90